PMA: in-depth investigation on deadlines, infertility, and gamete donation in the new report on the bioethics law

Financial coverage is part of the debate. The Academy recommends that these tests be covered by health insurance when carried out in the context of a parental project, with adapted information and genetic counseling. This point matters because accessible screening only to those who can pay would instate an additional inequality. The issue is not to make everyone a genetics expert but to offer a clear framework, with informed consent and understandable explanations.

From a public health perspective, this preconception screening directly interacts with medically assisted reproduction. Some couples might be directed earlier toward an ART path, others toward gamete donation, and others toward specific follow-up. This refers to medical research, as evaluating the relevance of screening panels, false positives, and real benefits requires solid data. Political decisions cannot rest solely on emotion or technological promise.

Finally, communication around these tests will need to avoid two pitfalls: dramatizing the risk for everyone, or minimizing the complexity of results. Genetic variations, probabilities, and notions of carrier status cannot be summarized in three slogans. Proper support can reduce anxiety, while blunt announcements can multiply it. This dimension is central because the goal is to shed light on a choice, not create additional worry in already challenging paths.

Quels sont les délais moyens mentionnés pour une PMA avec don de spermatozoïdes et avec don d’ovocytes ?

Le rapport parlementaire évoque environ un an et demi d’attente avant une première tentative de PMA avec don de spermatozoïdes, et environ deux ans lorsque le projet repose sur un don d’ovocytes. Ces durées sont des moyennes et peuvent varier selon les centres et les territoires, notamment en fonction des capacités et de la disponibilité des dons.

Pourquoi les femmes seules sont-elles autant représentées dans les demandes de PMA ?

Le rapport indique que les besoins des femmes seules ont été sous-estimés après l’ouverture permise par la loi bioéthique de 2021. Elles représentent désormais près de la moitié des personnes en attente d’une PMA avec don de spermatozoïdes. Cette évolution reflète une demande sociétale existante qui s’exprime davantage dès lors que l’accès est légalement ouvert et organisé.

Que signifie le manque de don de gamètes pour les parcours de procréation médicalement assistée ?

Un volume de dons insuffisant se traduit par des listes d’attente plus longues et des parcours difficiles à planifier. Le rapport évoque environ 1 000 donneurs de spermatozoïdes et 1 000 donneuses d’ovocytes par an en France, un niveau jugé trop faible au regard des besoins. Cela peut pousser certains à chercher une prise en charge ou une solution à l’étranger.

Le dépistage génétique préconceptionnel recommandé par l’Académie de médecine concerne-t-il uniquement la PMA ?

Non. Le rapport de l’Académie nationale de médecine adopté le 30 juin recommande ce dépistage pour les couples ayant un projet d’enfant, avant la grossesse. Les résultats peuvent orienter vers différentes options : poursuite du projet avec information, suivi prénatal, recours à une AMP avec diagnostic préimplantatoire, ou don de gamètes selon la situation et les choix des futurs parents.

On June 25, 2026, a parliamentary report from the Parliamentary Office for the Evaluation of Scientific and Technological Choices (OPECST) provides a first assessment, five years after the 2021 bioethics law that expanded access to assisted reproductive technology (ART) to single women and female couples. The document does not merely celebrate a societal opening: it addresses head-on the waiting times, hospital capacities, and the lack of gamete donation, using very “on the ground” vocabulary that resonates with all those who have spent more time in waiting rooms than on terraces. The figures mentioned remind us of a simple reality: medically assisted reproduction has become a public health issue, and not just a dinner discussion where everyone has a very strong opinion.

In this investigation, the points of friction are clear: requests are more numerous than expected, journeys stretch on to the point of straining the biological clock, and there are significant disparities between regions. In the background, infertility is increasing and is too often mistakenly mixed with the decline in birth rates. The report emphasizes medical and environmental causes, while some trajectories are further complicated by elective egg freezing, which has become a real phenomenon since 2021. At the same time, the National Academy of Medicine proposes to open preconception genetic screening, a debate that adds a layer of science (and paperwork) to already heavy journeys.

OPECST Report on the Bioethics Law: What the Survey Really Says About ART Waiting Times

The report published this June 25 shines a very clear spotlight on a word that ART patients know by heart: delays. The opening of ART access expanded the concerned public, but the organization did not accelerate at the same pace as the demand. Result: waiting becomes a medical parameter in its own right, not just a simple logistical annoyance. In a medically assisted reproduction path, a few months can change the probabilities, especially when maternal age advances and protocols follow each other with sometimes narrow biological windows.

The average durations mentioned set a concrete framework. The report talks about approximately one and a half years before a first ART attempt with sperm donation, two years when the project requires egg donation, and about one year for elective egg freezing. These figures do not only tell a schedule story: they describe a path lived at the pace of appointments, assessments, administrative validations, and laboratory availabilities. In real life, this also means taking time off, organizing trips, and a mental load that loves to show up uninvited.

The report also emphasizes the relative stabilization recently observed, but stabilizing a long delay does not make it short. The nuance is important for public understanding: if a waiting line stops growing, those already in line do not teleport to the counter. The gap between the macro announcement (a tension that “stabilizes”) and the micro experience (an appointment in eight months) fuels a frequent misunderstanding, sometimes directed against medical teams while they deal with technical platforms and saturated schedules.

Another salient point: territorial disparities. The same parental project can take very different shapes depending on the center, the population area, and local capacities in biologists, gynecologists, midwives, psychologists, or counselors. The report describes these gaps as an access to care problem. For the public, this translates into very concrete adaptive strategies: expanding the search zone for a center, accepting long trips, juggling professional constraints, or ending up comparing waiting times like train connection times, but with much fewer coffees on the platform.

The issue of “loss of chances” comes back because female fertility decreases with age, especially after 35 years old. The report does not make this a slogan; it makes it a health issue. Waiting is therefore not just discomfort: it becomes a variable that affects the probability of pregnancy and the number of attempts needed. This mechanism explains why some paths can shift from a relatively simple project to a more medicalized path, with heavier protocols and cumulative fatigue.

Demand for ART and Elective Egg Freezing: A Load Increase Faster than Centers’ Capacities

The inquiry contained in the report highlights a dynamic that surprised by its scale: ART demand increased faster than expected after the bioethics law. The document insists on one specific point: the needs of single women were underestimated. They now represent nearly half of the people waiting for ART with sperm donation. This shift is not anecdotal, as it changes the structure of demand, volumes to be processed, and the organization of consultations.

In fact, the load increase is not limited to sperm donation. Another phenomenon has established itself in the landscape since 2021: the elective egg freezing. Between 2021 and 2025, over 60,000 requests were recorded in France, while about 18,000 women actually accessed the procedure due to insufficient capacity in authorized facilities. These figures provide a glimpse of the gap between intention and realization, with a very concrete bottleneck: technical platforms, team availability, and access to retrieval slots.

In an elective egg freezing path, time is not only a line on a calendar. An initial consultation is required, an assessment (often hormonal and ultrasound), stimulation, retrieval, then vitrification and storage. Each step depends on fine coordination between patients, healthcare teams, and labs. When slots are missing, the path fragments, and the experience can become a succession of “come back later,” medical version. The “funny” side of the situation is that in 2026, one can track a parcel in real time, but not always obtain a firm date for a scheduled medical procedure.

The report also highlights an organizational point: opening new rights is not enough if healthcare provision does not keep up. Increasing capacities cannot be decreed snap-finger style, because trained staff, operating room time, biologists, quality circuits, and regulation are required. Medical research plays an indirect but real role: it structures good practices, protocols, and the evaluation of results, which then conditions system confidence. Without a solid base, the load increase happens at the cost of internal tensions and delays which impact patients and their relatives.

The report also points out the psychological dimension: the longer the wait, the more uncertainty becomes a stress factor. This stress is not “in the head” in the trivial sense: it influences quality of life, adherence to protocols, relationship to the body, and sometimes the ability to maintain professional balance. In daily life, it feels like a life put on hold, where projects are negotiated around medical appointments and cycles, with a feeling of never being able to plan “normally.”

To visualize gaps and points of friction, a table compares some benchmarks from the report’s findings.

The load increase described by the report has an easily missed consequence: more requests also mean more need for clear information, to avoid people entering a path discovering too late the delays, steps, and decision points. A well-marked path does not mechanically shorten waiting, but it prevents uncertainty from adding its own layer of fatigue.

Gamete Donation: Shortages, Imports, and Overseas Paths, the Domino Effects on Medically Assisted Reproduction

The report points a major brake in the paths: the gamete donation, with a level of donations deemed insufficient given the needs. It mentions about 1,000 sperm donors and 1,000 egg donors recorded annually in France. In an ART mechanism, this number is not just an indicator: it transforms into waiting lists, prioritizations, and calendars that lengthen as soon as one link is missing.

This deficit is not mysterious: donation requires time, appointments, exams, and emotional availability. Many still think donation is complicated or intrusive, while a part of the barrier is logistics and lack of information. The report recommends strengthening campaigns and improving center organization to ease donation. On a very concrete level, this means clearer paths, better-coordinated appointments, and schedules compatible with active life. A campaign without available slots is a bit like opening a bakery without flour: the intention is there, but execution falters.

When resources are lacking, some centers turn abroad to supply sperm, a legal but debated practice. The subject is not only technical: it concerns health sovereignty, traceability, and the French system’s ability to meet demand created by the bioethics law. The report also mentions another effect: more and more people turn to overseas paths, mainly in Spain, when waiting in France seems incompatible with their situation.

This demand displacement appears in a specific indicator: reimbursement requests for ART performed abroad doubled between 2019 and 2025, according to information relayed in the report. For families, it means upfront costs, travel, and more complex medical coordination upon return (pregnancy follow-up, record transmission, continuity of care). For the system, it creates a paradox: France bears part of the consequences (follow-ups, reimbursements, support) while letting part of the procedures happen elsewhere due to insufficient local offer.

The report also highlights the issue of disparities: depending on the territories, access to gamete donation can become a kind of geographic lottery. National rules are the same, but resources are not always. Patients and couples find themselves “optimizing” their path by making multiple calls and monitoring slot openings. The situational comedy exists, but it costs a lot of energy: spending a morning refreshing a PMA center’s messaging system is not exactly the official definition of well-being.

A simple list helps understand where blockages nest when gamete donation does not keep up with demand:

• Fewer gametes available means more time between medical decision and effective attempt.
• Paths with egg donation are particularly tense because the donation is more medically constraining.
• Protocol planning becomes more difficult, with cancellations or postponements linked to availabilities.
• Travel to other regions increases, with indirect costs (transport, lodging, days off).
• Departures abroad may accelerate, then complicate continuity of care upon return.

The discussion on donation finally refers to a question of trust. Since the bioethics law, access to origins has evolved for people born from a donation, which can influence the decision to donate. Transparency and support matter, because donation is not a trivial act: it involves representations, values, and an organization that must remain solid to protect donors, recipients, and children.

Infertility and Fertility: A Public Health Issue Distinct from the Decline in Birth Rates

The report stresses a useful point, because it avoids confused debates: infertility is not the same as a decline in birth rates. Infertility relates to medical causes and risk factors, while birth rates also depend on economic, social, and cultural variables. Mixing the two often leads to poorly targeted public policies: one may want to “boost births” without better preventing infertility causes, leaving concerned people with slogans and few solutions.

The causes mentioned are multiple. The report cites pathologies, lifestyle factors, and exposure to reprotoxic substances, including some endocrine disruptors or environmental pollutants. The idea is not to scare but to remind that fertility also depends on the environment and overall health state. The document also points out that male and female causes appear in comparable proportions, a useful reminder in a universe where mental and medical burdens often weigh more on women.

A figure gives a measure of the place taken by medically assisted reproduction in parenthood paths: in 2023, more than 28,000 children were born through ART in France, representing nearly 4% of births. In other words, these techniques are no longer marginal. They structure a visible part of births, pregnancy follow-ups, and support needs. This justifies treating infertility as a public health issue, with prevention, diagnosis, care, and medical research.

Regarding prevention, several levers already exist, without turning every meal into a toxicology lecture. Information about age and fertility remains important because it enables informed choices, including for those who will never undergo ART. Public health actions can also target earlier screening and diagnostic paths to avoid medical wandering for several years. The report aligns with this logic by reminding that waiting is not just a “scheduling” issue but a variable interacting with biological realities.

In the daily life of those concerned, infertility often translates into a succession of steps: consultations, exams, sometimes unclear announcements, then referral to ART. This trajectory carries a psychological, social, and professional cost. Work stoppages, daytime appointments, and the discretion needed at work can become a second full-time job. Humor sometimes serves as a valve: calling one’s file “the soap opera” can help endure, but it does not replace smoother care organization.

The report also puts the question of inequalities into perspective. A person with flexible hours, a car, and ability to move does not face the same reality as a person relying on transport, with childcare constraints or shift work. Delays here are not neutral: they increase the gaps between those able to adapt and others. The expected response thus looks like an access-to-care policy, not just an internal center improvement.

Preconception Genetic Screening: The Academy of Medicine’s Recommendation and Its Implications in ART

On June 30, 2026, the National Academy of Medicine adopted a report recommending authorizing preconception genetic screening for couples having a child project. Today, this type of test is described as mostly possible when there is already a family history of severe genetic disease. The recommendation changes the perspective: it is about informing upstream, before a pregnancy starts, about the risk of transmitting certain severe recessive diseases.

The Academy’s report cites examples of affected pathologies, such as cystic fibrosis, spinal muscular atrophy, or certain forms of myopathy. The stated goal is to identify high-risk couples, then present them with medical and reproductive options. Within an ART framework, this may include preimplantation diagnosis. Outside of it, it may involve prenatal diagnosis, recourse to gamete donation, or choosing to pursue the parental project with full information. The key point is anticipation: moving information before pregnancy helps avoid decisions made in emotional urgency.

The recommendation fits in the continuity of existing schemes in France, such as prenatal and preimplantation diagnosis. However, it raises very concrete organizational questions: who prescribes, who explains, how long is the path, what genetic counseling support is available, and how to avoid creating a new bottleneck. If the ART system is already under pressure, adding a screening layer without strengthening genetics teams could extend some delays, even when the intention is to improve information.

Financial coverage is part of the debate. The Academy recommends that these tests be covered by health insurance when carried out in the context of a parental project, with adapted information and genetic counseling. This point matters because accessible screening only to those who can pay would instate an additional inequality. The issue is not to make everyone a genetics expert but to offer a clear framework, with informed consent and understandable explanations.

From a public health perspective, this preconception screening directly interacts with medically assisted reproduction. Some couples might be directed earlier toward an ART path, others toward gamete donation, and others toward specific follow-up. This refers to medical research, as evaluating the relevance of screening panels, false positives, and real benefits requires solid data. Political decisions cannot rest solely on emotion or technological promise.

Finally, communication around these tests will need to avoid two pitfalls: dramatizing the risk for everyone, or minimizing the complexity of results. Genetic variations, probabilities, and notions of carrier status cannot be summarized in three slogans. Proper support can reduce anxiety, while blunt announcements can multiply it. This dimension is central because the goal is to shed light on a choice, not create additional worry in already challenging paths.

Quels sont les délais moyens mentionnés pour une PMA avec don de spermatozoïdes et avec don d’ovocytes ?

Le rapport parlementaire évoque environ un an et demi d’attente avant une première tentative de PMA avec don de spermatozoïdes, et environ deux ans lorsque le projet repose sur un don d’ovocytes. Ces durées sont des moyennes et peuvent varier selon les centres et les territoires, notamment en fonction des capacités et de la disponibilité des dons.

Pourquoi les femmes seules sont-elles autant représentées dans les demandes de PMA ?

Le rapport indique que les besoins des femmes seules ont été sous-estimés après l’ouverture permise par la loi bioéthique de 2021. Elles représentent désormais près de la moitié des personnes en attente d’une PMA avec don de spermatozoïdes. Cette évolution reflète une demande sociétale existante qui s’exprime davantage dès lors que l’accès est légalement ouvert et organisé.

Que signifie le manque de don de gamètes pour les parcours de procréation médicalement assistée ?

Un volume de dons insuffisant se traduit par des listes d’attente plus longues et des parcours difficiles à planifier. Le rapport évoque environ 1 000 donneurs de spermatozoïdes et 1 000 donneuses d’ovocytes par an en France, un niveau jugé trop faible au regard des besoins. Cela peut pousser certains à chercher une prise en charge ou une solution à l’étranger.

Le dépistage génétique préconceptionnel recommandé par l’Académie de médecine concerne-t-il uniquement la PMA ?

Non. Le rapport de l’Académie nationale de médecine adopté le 30 juin recommande ce dépistage pour les couples ayant un projet d’enfant, avant la grossesse. Les résultats peuvent orienter vers différentes options : poursuite du projet avec information, suivi prénatal, recours à une AMP avec diagnostic préimplantatoire, ou don de gamètes selon la situation et les choix des futurs parents.